MT Genex Corporation
MT Genex Corporation Fundamental Analysis
MT Genex Corporation (9820.T) shows moderate financial fundamentals with a PE ratio of 12.91, profit margin of 6.94%, and ROE of 7.39%. The company generates $4.5B in annual revenue with moderate year-over-year growth of 4.21%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.6/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 9820.T's fundamental strength across five key dimensions:
Efficiency Score
Weak9820.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent9820.T trades at attractive valuation levels.
Growth Score
Weak9820.T faces weak or negative growth trends.
Financial Health Score
Excellent9820.T maintains a strong and stable balance sheet.
Profitability Score
Weak9820.T struggles to sustain strong margins.
Key Financial Metrics
Is 9820.T Expensive or Cheap?
P/E Ratio
9820.T trades at 12.91 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 9820.T's PEG of 0.66 indicates potential undervaluation.
Price to Book
The market values MT Genex Corporation at 0.93 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.42 times EBITDA. This signals the market has high growth expectations.
How Well Does 9820.T Make Money?
Net Profit Margin
For every $100 in sales, MT Genex Corporation keeps $6.94 as profit after all expenses.
Operating Margin
Core operations generate 10.71 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.39 in profit for every $100 of shareholder equity.
ROA
MT Genex Corporation generates $5.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
MT Genex Corporation generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
MT Genex Corporation generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
9820.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.91
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.66
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.93
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.90
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.77
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How 9820.T Stacks Against Its Sector Peers
| Metric | 9820.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.91 | 25.83 | Better (Cheaper) |
| ROE | 7.39% | 1278.00% | Weak |
| Net Margin | 6.94% | -43774.00% (disorted) | Weak |
| Debt/Equity | 0.02 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 7.77 | 10.63 | Strong Liquidity |
| ROA | 5.86% | -1539613.00% (disorted) | Weak |
9820.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews MT Genex Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
20.99%
Industry Style: Cyclical, Value, Infrastructure
High GrowthEPS CAGR
-23.44%
Industry Style: Cyclical, Value, Infrastructure
DecliningFCF CAGR
42.61%
Industry Style: Cyclical, Value, Infrastructure
High Growth